Monthly RoundUp: April 2021


Jayne Watson

Episode Description

In this month’s episode, the P4A team take a deep dive into the impact of Brexit on the UK’s market access landscape. Four months after leaving the European Union, the UK’s attractiveness as a key destination for commercialisation of new drugs is being tested. In order to improve its credentials, the UK is exploring a slew of measures that could potentially spark a reform.

But will that happen? P4A’s Joanna Fernandes and Jayne Watson consider two distinct initiatives – MHRA’s (Medicines Healthcare Regulatory Agency’s) new I-LAP (Innovative Licensing and Access Pathway) scheme and England’s HTA body NICE’s (National Institute for Health and Care Excellence’s) method review.

Other contributors: Jayne Watson

Producer: Aparna Krishnan

Latest episodes

Share this podcast